HLA - DR4与格雷夫斯眼病患者对皮质类固醇的反应相关。

HLA-DR4 associated response to corticosteroids in Graves' ophthalmopathy patients.

作者信息

van der Gaag R, Wiersinga W M, Koornneef L, Mourits M P, Prummel M F, Berghout A, de Vries R R, Schreuder G M, D'Amaro J

机构信息

Department of Ophthalmo-Immunology, The Netherlands Ophthalmic Research Institute, Amsterdam.

出版信息

J Endocrinol Invest. 1990 Jun;13(6):489-92. doi: 10.1007/BF03348605.

DOI:10.1007/BF03348605

PMID:2258577

Abstract

Fifty-seven patients with severe Graves' ophthalmopathy were treated with corticosteroids. Therapeutic outcome was assessed according to predetermined criteria as response (n = 37) or non-response (n = 20) to therapy. Patients were typed for HLA-A, -B, -C, -DR and -DQ. HLA-DR4 was completely absent in the 20 non-responder patients (corrected p value = 0.042). In the responder group 14 of the 37 patients were HLA-DR4 positive. This study shows that in Graves' ophthalmopathy patients the presence of HLA-DR4 is associated with a good response to corticosteroid therapy. The frequency of HLA-DR4 in the Graves' ophthalmopathy population as a whole, however, was not different from normal (25% versus 26%). But as reported previously, the frequency of HLA-DR3 was significantly increased in the Graves' ophthalmopathy patients when compared to healthy blood donors (47% versus 24%, corrected p value = 0.02). No significant deviations were found in the HLA-A, -B, or -C loci.

摘要

57例重度格雷夫斯眼病患者接受了皮质类固醇治疗。根据预先确定的标准评估治疗结果，分为治疗有反应组（n = 37）和无反应组（n = 20）。对患者进行了HLA - A、- B、- C、- DR和 - DQ分型。20例无反应患者中完全不存在HLA - DR4（校正p值 = 0.042）。在有反应组的37例患者中，14例HLA - DR4呈阳性。本研究表明，在格雷夫斯眼病患者中，HLA - DR4的存在与皮质类固醇治疗的良好反应相关。然而，格雷夫斯眼病总体人群中HLA - DR4的频率与正常人群无差异（25%对26%）。但如先前报道，与健康献血者相比，格雷夫斯眼病患者中HLA - DR3的频率显著增加（47%对24%，校正p值 = 0.02）。在HLA - A、- B或 - C位点未发现显著偏差。